NCT00757042View on ClinicalTrials.gov

Safety Study of Tezepelumab (AMG 157) in Healthy Adults and Adults With Atopic Dermatitis

PHASE1CompletedINTERVENTIONAL

Enrollment

78

Participants

Timeline

Start Date

September 18, 2008

Primary Completion Date

January 5, 2011

Study Completion Date

January 5, 2011

Conditions

Atopic DermatitisHealthy Volunteers

Interventions

DRUG

Tezepelumab

Administered by subcutaneous or intravenous injection

DRUG

Placebo

Matching placebo administered by subcutaneous or intravenous injection.

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Amgen

INDUSTRY